Supplementary Material for: Premature Stroke Secondary to Severe Hypertension Results from Liddle Syndrome Caused by a Novel SCNN1B Mutation

<b><i>Introduction:</i></b> Liddle syndrome (LS), an autosomal dominant and inherited monogenic hypertension syndrome caused by pathogenic mutations in the epithelial sodium channel (ENaC) genes <i>SCNN1A,</i> <i>SCNN1B</i>, and <i>SCNN1G</i>. <b><i>Objective:</i></b> This study was designed to identify a novel <i>SCNN1B</i> missense mutation in a Chinese family with a history of stroke, and to confirm that the identified mutation is responsible for LS in this family. <b><i>Methods:</i></b> DNA samples were collected from the proband and 11 additional relatives. Next-generation sequencing was performed in the proband to find candidate variants. In order to exclude genetic polymorphism, the candidate variant<i></i>in<i> SCNN1B</i> was verified in other family members, 100 hypertensives, and 100 healthy controls by Sanger sequencing. <b><i>Results:</i></b> Genetic testing revealed<b><i></i></b>a novel and rare heterozygous variant in <i>SCNN1B</i> in the proband. This variant resulted in a substitution of threonine instead of proline at codon 617, altering the PY motif of β-ENaC. The identified mutation was only verified in 5 relatives. In silico analyses indicated that this variant was highly pathogenic. In this family, phenotypic heterogeneity was present among 6 LS patients. Tailored medicine with amiloride was effective in controlling hypertension and improving the serum potassium concentration in patients with LS. <b><i>Conclusions:</i></b><i></i>We identified a novel <i>SCNN1B</i> mutation (c.1849C&gt;A) in a family affected by LS. Patients with LS, especially those with severe hypertension, should be alert for the occurrence of premature stroke. Timely diagnosis using genetic testing and tailored treatment with amiloride can help LS patients to avoid severe complications.